Synthesis and biological activity of new rhodanine-triazole conjugates with 2-(2,6-dichlorophenylamino)benzyl moiety in the molecules

Authors

  • Yu. L. Shepeta Vinnytsia National Pirogov Memorial Medical University, Ukraine,
  • O. M. Roman Danylo Halytsky Lviv National Medical University, Ukraine,
  • I. O. Nektiehaiev Danylo Halytsky Lviv National Medical University, Ukraine,
  • R. B. Lesyk Danylo Halytsky Lviv National Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2409-2932.2020.2.207024

Keywords:

synthesis, 4H-1, 2, 4-triazole, rhodanine, diclofenac, anti-inflammatory activity, anticancer activity

Abstract

Molecular design of “drug-like” molecules based on the combination of a fragment of non-steroidal anti-inflammatory drug diclofenac with a pharmacologically attractive 1,2,4-triazole and 4-thiazolidinone “structural matrices” in one molecule is an effective approach in modern medical chemistry.

Aim. Synthesis of new rhodanine-triazole hybrid molecules (conjugates) with 2- (2,6-dichlorophenylamino) benzyl moiety and evaluation of their biological activity.

Materials and methods. The method of rhodanine-triazoles synthesis was elaborated. The structures of the synthesized compounds were confirmed by elemental analysis, NMR spectroscopy, and LCMS. The anti-exudative activity of the compounds was investigated in a rat carrageenan edema model, and the antitumor effect was studied in vitro at a concentration of 10-5 M on 60 cancer cell lines (DTP NCI Program).

Results. Novel 2-{5-[2-(2,6-dichlorophenylamino)-benzyl]-4H-1,2,4-triazol-3-ylsulfanyl}-N-(4-oxo-2-thioxothiazolidin-3-yl)-acetamides and their 5-arylidene derivatives were synthesized/ Among these derivatives hit compounds with anti-inflammatory and anticancer activity against cell lines of melanoma, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, ovarian cancer, renal cancer, and breast cancer were identified.

Conclusion. The molecular design of rhodanine-triazole hybrid molecules based on diclofenac is an effective approach to the search for novel anti-inflammatory and antitumor agents.

References

Palkar, M. B., Singhai, A. S., Ronad, P. M., Vishwanathswamy, A. H. M., Boreddy, T. S., Veerapur, V. P., Shaikh, M. S., Rane, R. A., & Karpoormath, R. (2014). Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorganic & Medicinal Chemistry, 22(10), 2855-2866. https://doi.org/10.1016/j.bmc.2014.03.043

Kumar, S. S., & Kavitha, H. P. (2013). Synthesis and Biological Applications of Triazole Derivatives – A Review. Mini-Reviews in Organic Chemistry, 10(1), 40-65. https://doi.org/10.2174/1570193X11310010004

Havrylyuk, D., Roman, O., & Lesyk, R. (2016). Synthetic approaches, structure activity relationship and biological applications for pharmacolo­gically attractive pyrazole/pyrazoline-thiazolidine-based hybrids. European Journal of Medicinal Chemistry, 113, 145-166. https://doi.org/10.1016/j.ejmech.2016.02.030

Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017). 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistry. European Journal of Medicinal Chemistry, 140, 542-594. https://doi.org/10.1016/j.ejmech.2017.09.031

Kaminskyy, D., Kryshchyshyn, A., & Lesyk, R. (2017b). Recent developments with rhodanine as a scaffold for drug discovery. Expert Opinion on Drug Discovery, 12(12), 1233-1252. https://doi.org/10.1080/17460441.2017.1388370

Amir, M., & Shikha, K. (2004). Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2- (2,6-dichloroanilino) phenyl acetic acid derivatives. European Journal of Medicinal Chemistry, 39(6), 535-545. https://doi.org/10.1016/j.ejmech.2004.02.008

Shepeta, Yu. L., Lelyukh, M. I., Zimenkovsky, B. S., Lesyk, R. B. (2016). Syntez novykh pokhidnykh 4N-1,2,4-triazol-3-tiolu z 2-(2,6-dykhlorofenilamino)benzylnym frahmentom u molekulakh ta yikhnia protyzapalna aktyvnist [Synthesis of novel 4H-1,2,4-triazole-3-thiol derivatives with 2-(2,6-dichlorophenylamino)benzyl moiety in molecules and their anti-inflammatory activity]. Current issues in pharmacy and medicine: science and practice, 20(1), 18-25. [in Ukrainian]. https://doi.org/10.14739/2409-2932.2016.1.61103

Nektegayev, I., & Lesyk, R. (1999). 3-Oxyarylthiazolidones-4 and their choleretic activity. Scientia Pharmaceutica, 67, 227-230.

Havrylyuk, D., Mosula, L., Zimenkovsky, B., Vasylenko, O., Gzella, A., & Lesyk, R. (2010). Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety. European Journal of Medicinal Chemistry, 45(11), 5012-5021. https://doi.org/10.1016/j.ejmech.2010.08.008

Stefanov, O. V. (Ed.). (2001). Doklinichni doslidzennia likarskykh zasobiv : metodychni rekomendatsii [Preclinical studies of medicines: methodolo­gical recommendations]. Kyiv: Avitsenna. [in Ukrainian].

Grever, M. R., Schepartz, S. A., & Chabner, B. A. (1992). The National Cancer Institute: Cancer drug discovery and development program. Seminars in Oncology, 19(6), 622-638. https://doi.org/10.5555/uri:pii:009377549290032V

Boyd, M. R., & Pauli, K. D. (1995). Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Research, 34(2), 91-109. https://doi.org/10.1002/ddr.430340203

Popov-Pergal, K., Chekovich, Zh., & Pergal, M. (1991). Kondensatsiya 2,4-tetragidro-1,3-tiazola s aromaticheskimi aldegidami [Condensation of 2,4-tetrahydro-1,3-thiazole with aromatic aldehydes]. Zhurnal organi­cheskoi khimii, 61(9), 2112-2116. [in Russian].

Roman, O., & Lesyk, R. (2007). Synthesis and anticancer activity in vitro of some 2-thioxo-4-thiazolidone derivatives. Farmacia, 55(6), 640-648.

Downloads

How to Cite

1.
Shepeta YL, Roman OM, Nektiehaiev IO, Lesyk RB. Synthesis and biological activity of new rhodanine-triazole conjugates with 2-(2,6-dichlorophenylamino)benzyl moiety in the molecules. Current issues in pharmacy and medicine: science and practice [Internet]. 2020Jul.3 [cited 2024Dec.23];13(2). Available from: http://pharmed.zsmu.edu.ua/article/view/207024

Issue

Vol. 13 No. 2 (2020)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)